Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">On The Wires<ul><li>Golden Minerals Company (<strong>AUMN</strong>) announced that Minera Hecla S.A. de C.V. has exercised its right to extend the lease of Golden's oxide mill in Durango State, Mexico for an additional 18 months, through December 31, 2018. Additionally, Golden announces its filing of the National Instrument 43-101 compliant mineral resource estimate for the Santa Maria silver and gold project, under slightly amended terms from those announced in February 2017.</li><li>Emergent BioSolutions (<strong>EBS</strong>) announced that it has signed a modification to its contract with the Biomedical Advanced Research and Development Authority (BARDA) to manufacture and store bulk drug substance for its botulism antitoxin, BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) — (Equine)], valued at ~$53 mln with a five-year period of performance. This modification to the contract will enable future filling and deliveries of final drug product to the Strategic National Stockpile. BAT is indicated for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G in adults and pediatric patients.</li><li>Codexis, Inc. (<strong>CDXS</strong>) announced the signing of a multi-year development agreement with Tate & Lyle, a global provider of food ingredients and solutions. This is the second multi-year agreement signed in recent months between Codexis and Tate & Lyle and highlights Codexis' continued growth applying its CodeEvolver protein engineering platform technology in the food industry. This agreement strengthens the existing partnership between the two companies following the completion of a separate supply agreement in December 2016.</li><li>Endologix (<strong>ELGX</strong>) announced that the first patients were treated in the Expanding Patient Applicability with Polymer Sealing Ovation Alto Stent Graft (ELEVATE) IDE clinical study, the Company's pivotal clinical trial to evaluate the safety and effectiveness of the Ovation Alto Abdominal Stent Graft System for the repair of infrarenal abdominal aortic aneurysms. The ELEVATE IDE clinical trial is approved to enroll 75 patients at up to 12 centers in the U.S. Based on the anticipated enrollment timeline, co continues to expect Ovation Alto could be available in the U.S. in 2019.</li></ul></td> </tr></table>"